MG-132 [133407-82-6]

Cat# HY-13259-10mg

Size : 10mg

Brand : MedChemExpress

Request more information

Contact local distributor :


Phone : +1 850 650 7790

Description

MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis[1][2][3].

IC50 & Target

IC50: 100 nM (Proteasome), 1.2 μM (Calpain)[1][3]

Cellular Effect
Cell Line Type Value Description References
COS-7 IC50
< 10 μM
Compound: MG132
Cytotoxicity against african green monkey COS7 cells by XTT method
Cytotoxicity against african green monkey COS7 cells by XTT method
[PMID: 18088097]
HCT-116 IC50
0.82 μM
Compound: MG132
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 31312413]
HEK293 IC50
0.009 μM
Compound: MG132
Inhibition of chymotrypsin-like activity of proteasome beta-5 subunit in HEK293 cells using Suc-LLVY-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta5 assay
Inhibition of chymotrypsin-like activity of proteasome beta-5 subunit in HEK293 cells using Suc-LLVY-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta5 assay
[PMID: 23540790]
HEK293 IC50
0.6 μM
Compound: MG132
Inhibition of postacid activity of 20s proteasome beta-1 subunit in HEK293 cells using Z-nLPnLD-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta1 assay
Inhibition of postacid activity of 20s proteasome beta-1 subunit in HEK293 cells using Z-nLPnLD-Glo as substrate incubated for 2 hrs prior to substrate addition measured after 10 mins by cell-based proteasome-Glo beta1 assay
[PMID: 23540790]
Huh-7 IC50
< 10 μM
Compound: MG132
Cytotoxicity against human HuH7 cells by XTT method
Cytotoxicity against human HuH7 cells by XTT method
[PMID: 18088097]
MCF-10A IC50
0.29 μM
Compound: MG-132
Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay
Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay
[PMID: 24153206]
MCF7 IC50
0.13 μM
Compound: MG-132
Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay
Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay
[PMID: 24153206]
MDA-MB-231 IC50
0.18 μM
Compound: MG-132
Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay
Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay
[PMID: 24153206]
NCI-H23 IC50
0.48 μM
Compound: MG-132
Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
[PMID: 30964987]
NCI-H727 IC50
0.98 μM
Compound: MG-132
Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
[PMID: 30964987]
NCI-H929 IC50
0.17 μM
Compound: MG-132
Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay
Cytotoxicity against human NCI-H929 cells after 3 days by Alamar blue assay
[PMID: 24625088]
OCI-Ly3 IC50
> 10 μM
Compound: 1, MG-132
Cytotoxicity against NF-kappaB overexpressing human OCI-Ly3 cells after 4 hrs
Cytotoxicity against NF-kappaB overexpressing human OCI-Ly3 cells after 4 hrs
[PMID: 18024113]
RAW264.7 IC50
0.08 μg/mL
Compound: MG132
Inhibition of LPS and IFN-gamma-stimulated nitric oxide production in mouse RAW264.7 cells after 18 hrs by Griess method
Inhibition of LPS and IFN-gamma-stimulated nitric oxide production in mouse RAW264.7 cells after 18 hrs by Griess method
[PMID: 26351042]
RAW264.7 IC50
0.08 μM
Compound: MG-132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent method
[PMID: 22620677]
RAW264.7 IC50
0.1 μM
Compound: MG132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 18 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 18 hrs by Griess method
[PMID: 33422907]
RAW264.7 IC50
0.1 μM
Compound: MG-132
Inhibition of LPS-stimulated NO production in mouse RAW264.7 cells after 18 hrs by Griess assay
Inhibition of LPS-stimulated NO production in mouse RAW264.7 cells after 18 hrs by Griess assay
[PMID: 24219809]
RAW264.7 IC50
0.1 μM
Compound: MG-132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess method
[PMID: 23819871]
RAW264.7 IC50
0.1 μM
Compound: MG132
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
[PMID: 24597894]
RAW264.7 IC50
0.1 μM
Compound: MG-132
Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 18 hrs by griess reagent based plate reader analysis
Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 18 hrs by griess reagent based plate reader analysis
[PMID: 24697496]
RAW264.7 IC50
0.15 μM
Compound: MG-132
Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 25 uM preincubated with compound followed by LPS challenge measured after 18 hrs by Griess method
Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 25 uM preincubated with compound followed by LPS challenge measured after 18 hrs by Griess method
[PMID: 26757019]
RAW264.7 IC50
0.15 μM
Compound: MG-132
Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells measured after 18 hrs by Griess reagent based multilabel plate reader analysis
Inhibition of nitric oxide production in LPS-stimulated mouse RAW264.7 cells measured after 18 hrs by Griess reagent based multilabel plate reader analysis
[PMID: 23327668]
RAW264.7 IC50
0.16 μM
Compound: MG-132
Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent based assay
Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production after 18 hrs by Griess reagent based assay
[PMID: 30629435]
RAW264.7 IC50
0.17 μg/mL
Compound: MG-132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 5 mins by Greiss method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 5 mins by Greiss method
[PMID: 22277277]
RAW264.7 IC50
0.17 μg/mL
Compound: MG-132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFNgamma-induced NO production after 5 mins by Greiss method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFNgamma-induced NO production after 5 mins by Greiss method
[PMID: 22277277]
RAW264.7 IC50
0.18 μM
Compound: MG-132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by Griess assay
[PMID: 27203291]
RAW264.7 IC50
0.2 μM
Compound: MG132
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated iNOS activity preincubated with compound for 24 hrs followed by LPS stimulation for 2 hrs and measured 2 hrs after NADPH addition by fluorescence based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated iNOS activity preincubated with compound for 24 hrs followed by LPS stimulation for 2 hrs and measured 2 hrs after NADPH addition by fluorescence based assay
[PMID: 33454546]
RAW264.7 IC50
0.2 μM
Compound: MG132
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells preincubated with compound for 24 hrs followed by LPS stimulation and measured after 2 hrs by Griess reagent-based assay
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells preincubated with compound for 24 hrs followed by LPS stimulation and measured after 2 hrs by Griess reagent-based assay
[PMID: 33454546]
RAW264.7 IC50
0.2 μM
Compound: MG-132
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 18 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 18 hrs by Griess assay
[PMID: 29338260]
RAW264.7 IC50
0.35 μM
Compound: MG-132
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 18 hrs
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 18 hrs
[PMID: 21044847]
RAW264.7 IC50
0.35 μM
Compound: MG-132
Inhibition of NO production in Interferon gamma-stimulated mouse RAW264.7 cells after 18 hrs
Inhibition of NO production in Interferon gamma-stimulated mouse RAW264.7 cells after 18 hrs
[PMID: 21044847]
RAW264.7 IC50
0.63 μM
Compound: MG132
Toxicity against mouse RAW264.7 cells by XTT assay
Toxicity against mouse RAW264.7 cells by XTT assay
[PMID: 22858297]
RAW264.7 IC50
2.6 μM
Compound: MG132
Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation for 12 hrs by Griess reagent based analysis
Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated with compound for 2 hrs followed by LPS stimulation for 12 hrs by Griess reagent based analysis
[PMID: 36607819]
SW480 IC50
29.5 μM
Compound: MG132
Inhibition of NFkappaB transcription in human SW480 cells at by luciferase reporter gene assay
Inhibition of NFkappaB transcription in human SW480 cells at by luciferase reporter gene assay
[PMID: 26841168]
In Vitro

MG-132 (Z-Leu-Leu-Leu-al) initiates neurite outgrowth in PC12 cells at a low concentration (30 nM) and is a very strong inhibitor of 20S proteasome[3].
MG-132 (10 μM; 1 hour) reverses the effects of TNF- α on I κ B degradation and NF-κ B activation in A549 cells[4].
MG-132 (0.75-5 μM; 24 hours) potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition[5].
MG-132 (10-40 μM; 24 hours) significantly reduces the viability of C6 glioma cells in both time- and concentration-dependent manners and shows the IC50 of 18.5 μM at 24 hours[6].
MG-132 (18.5 μM; 24 hours) induces down-regulation of anti-apoptotic proteins Bcl-2 and XIAP and up-regulates expression of pro-apoptotic protein Bax and caspase-3[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: C6 glioma cells
Concentration: 10, 20, 30, 40 μM
Incubation Time: 24 hours
Result: Significantly reduced the viability of C6 glioma cells beginning at 6 h in both time- and concentration-dependent manners and showed the IC50 of 18.5 μM at 24 hours.

Western Blot Analysis[3]

Cell Line: A549 cells
Concentration: 10 μM
Incubation Time: 1 hour
Result: Reversed the effects of TNF-α on IκB degradation and resulted in a reversal of TNF-α-induced NF-κB activation.
In Vivo

MG132 (10 mg/kg; i.p.; daily for 25 days starting 5 days after EC9706 cells injection) significantly inhibits tumor growth of the EC9706 xenograft without causing toxicity to mice[7].
MG-132 (1 mg/kg; i.v.; twice a week for 4 weeks) shows potent tumor inhibitory effect against mice bearing HeLa tumors[8].
MG-132 (1-10 μg/kg/24 hours; subcutaneously implanted osmotic pumps; for 8 days) greatly increases the expression levels of β-dystroglycan, α-dystroglycan, α-sarcoglycan, and dystrophin in skeletal muscle lysates in mice (six-month-old male C57BL/10ScSn DMD mdx mice)[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 5- to 6-weeks old female athymic nude mice (EC9706 xenograft)
Dosage: 10 mg/kg
Administration: I.p.; daily for 25 days starting 5 days after EC9706 cells injection
Result: Significantly inhibited tumor growth of the EC9706 xenograft without causing toxicity to the mice.
Animal Model: Five-week-old female C.B-17/lcr-scid/scidJcl mice (bearing HeLa cells)[8]
Dosage: 1 mg/kg
Administration: Intravenous injection; twice a week for 4 weeks
Result: The growth inhibition rates in HeLa tumors was 49% compared to the control.
Molecular Weight

475.62

Formula

C26H41N3O5

CAS No.
Appearance

Solid

Color

White to yellow

SMILES

O=C(OCC1=CC=CC=C1)N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C(23)=O)CC(C)C)=O)=O)CC(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (210.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1025 mL 10.5126 mL 21.0252 mL
5 mM 0.4205 mL 2.1025 mL 4.2050 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.67 mg/mL (3.51 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 1.67 mg/mL (3.51 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
AAH-CYT-1-2
 2SampleKit 
AAH-INF-1-8
 8SampleKit